View ValuationOrion Pharma 将来の成長Future 基準チェック /06現在、 Orion Pharmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長16.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Farzana Khan was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 24Orion Pharma Limited to Report Q3, 2026 Results on Apr 29, 2026Orion Pharma Limited announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 25Orion Pharma Limited to Report Q2, 2026 Results on Jan 29, 2026Orion Pharma Limited announced that they will report Q2, 2026 results on Jan 29, 2026お知らせ • Nov 12Orion Pharma Limited, Annual General Meeting, Dec 23, 2025Orion Pharma Limited, Annual General Meeting, Dec 23, 2025, at 16:00 Central Asia Standard Time. Location: hybrid platform at orion house, 153-154, tejgaon i/a, dhaka-1208, dhaka Bangladeshお知らせ • Nov 11Orion Pharma Limited to Report Q1, 2026 Results on Nov 15, 2025Orion Pharma Limited announced that they will report Q1, 2026 results on Nov 15, 2025お知らせ • Nov 04Orion Pharma Limited to Report Fiscal Year 2025 Results on Nov 11, 2025Orion Pharma Limited announced that they will report fiscal year 2025 results on Nov 11, 2025お知らせ • Apr 23Orion Pharma Limited to Report Q3, 2025 Results on Apr 29, 2025Orion Pharma Limited announced that they will report Q3, 2025 results on Apr 29, 2025お知らせ • Jan 26Orion Pharma Limited to Report Q2, 2025 Results on Jan 29, 2025Orion Pharma Limited announced that they will report Q2, 2025 results on Jan 29, 2025Declared Dividend • Nov 16Dividend of ৳1.00 announcedDividend of ৳1.00 is the same as last year. Ex-date: 5th December 2024 Payment date: 26th January 2025 Dividend yield will be 2.3%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (51% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 86 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 43% to shift the payout ratio to a potentially unsustainable range, which is more than the 12% EPS decline seen over the last 5 years.お知らせ • Nov 14Orion Pharma Limited, Annual General Meeting, Dec 26, 2024Orion Pharma Limited, Annual General Meeting, Dec 26, 2024, at 15:30 Central Asia Standard Time.お知らせ • Nov 08Orion Pharma Limited to Report Fiscal Year 2024 Results on Nov 13, 2024Orion Pharma Limited announced that they will report fiscal year 2024 results on Nov 13, 2024New Risk • Nov 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.2% operating cash flow to total debt). Earnings have declined by 6.1% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (৳9.73b market cap, or US$81.3m).Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ৳37.80, the stock trades at a trailing P/E ratio of 19.4x. Average trailing P/E is 18x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 57% over the past three years.Valuation Update With 7 Day Price Move • Oct 02Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ৳34.10, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 68% over the past three years.New Risk • Aug 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ৳11.8b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.2% operating cash flow to total debt). Earnings have declined by 6.1% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (৳11.8b market cap, or US$98.7m).Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳0.42 (vs ৳0.53 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.42 (down from ৳0.53 in 3Q 2023). Revenue: ৳2.04b (down 11% from 3Q 2023). Net income: ৳99.2m (down 20% from 3Q 2023). Profit margin: 4.9% (down from 5.4% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.お知らせ • Apr 26Orion Pharma Limited to Report Q3, 2024 Results on Apr 29, 2024Orion Pharma Limited announced that they will report Q3, 2024 results on Apr 29, 2024New Risk • Dec 19New major risk - Revenue and earnings growthEarnings have declined by 1.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (13% operating cash flow to total debt). Debt is not well covered by operating cash flow (13% operating cash flow to total debt). Earnings have declined by 1.8% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (4.8% net profit margin). Profit margins are more than 30% lower than last year (4.8% net profit margin).Upcoming Dividend • Nov 27Upcoming dividend of ৳1.00 per share at 1.3% yieldEligible shareholders must have bought the stock before 04 December 2023. Payment date: 25 January 2024. Payout ratio is a comfortable 33% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).お知らせ • Nov 14Orion Pharma Limited, Annual General Meeting, Dec 26, 2023Orion Pharma Limited, Annual General Meeting, Dec 26, 2023, at 15:00 Bangladesh Standard Time.お知らせ • Nov 13Orion Pharma Limited to Report Q1, 2024 Results on Nov 14, 2023Orion Pharma Limited announced that they will report Q1, 2024 results on Nov 14, 2023お知らせ • Nov 07Orion Pharma Limited to Report Fiscal Year 2023 Results on Nov 12, 2023Orion Pharma Limited announced that they will report fiscal year 2023 results on Nov 12, 2023Reported Earnings • May 06Third quarter 2023 earnings released: EPS: ৳0.53 (vs ৳1.05 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.53 (down from ৳1.05 in 3Q 2022). Revenue: ৳2.30b (up 102% from 3Q 2022). Net income: ৳123.9m (down 50% from 3Q 2022). Profit margin: 5.4% (down from 22% in 3Q 2022). The decrease in margin was driven by higher expenses.Reported Earnings • Feb 14Second quarter 2023 earnings released: EPS: ৳1.19 (vs ৳1.72 in 2Q 2022)Second quarter 2023 results: EPS: ৳1.19 (down from ৳1.72 in 2Q 2022). Revenue: ৳4.00b (up 430% from 2Q 2022). Net income: ৳278.4m (down 31% from 2Q 2022). Profit margin: 7.0% (down from 53% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Nov 28Upcoming dividend of ৳1.00 per shareEligible shareholders must have bought the stock before 05 December 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).Valuation Update With 7 Day Price Move • Nov 20Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ৳85.00, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 196% over the past three years.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director A. N. M. Kashem was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Nov 15Orion Pharma Limited Recommends Cash Dividend for the Year Ended June 30, 2022Orion Pharma Limited Board of Directors has recommended 10% cash dividend for the year ended June 30, 2022.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ৳113, the stock trades at a trailing P/E ratio of 27.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 340% over the past three years.Valuation Update With 7 Day Price Move • Sep 22Investor sentiment improved over the past weekAfter last week's 29% share price gain to ৳150, the stock trades at a trailing P/E ratio of 36.4x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 432% over the past three years.Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to ৳126, the stock trades at a trailing P/E ratio of 30.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 349% over the past three years.Valuation Update With 7 Day Price Move • Aug 24Investor sentiment improved over the past weekAfter last week's 15% share price gain to ৳103, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 244% over the past three years.Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳92.10, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 21x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 197% over the past three years.Reported Earnings • Apr 30Third quarter 2022 earnings released: EPS: ৳1.05 (vs ৳0.95 in 3Q 2021)Third quarter 2022 results: EPS: ৳1.05 (up from ৳0.95 in 3Q 2021). Revenue: ৳1.14b (down 53% from 3Q 2021). Net income: ৳245.5m (up 10% from 3Q 2021). Profit margin: 22% (up from 9.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director A. N. M. Kashem was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Feb 01Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳1.72 (up from ৳1.21 in 2Q 2021). Revenue: ৳754.3m (down 69% from 2Q 2021). Net income: ৳402.3m (up 42% from 2Q 2021). Profit margin: 53% (up from 12% in 2Q 2021). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 42% per year, which means it is well ahead of earnings.Upcoming Dividend • Nov 23Upcoming dividend of ৳1.20 per shareEligible shareholders must have bought the stock before 30 November 2021. Payment date: 18 January 2022. Trailing yield: 1.2%. Lower than top quartile of Bangladeshi dividend payers (2.9%). Lower than average of industry peers (1.7%).Valuation Update With 7 Day Price Move • Oct 11Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳112, the stock trades at a trailing P/E ratio of 36.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 231% over the past three years.Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improved over the past weekAfter last week's 24% share price gain to ৳84.40, the stock trades at a trailing P/E ratio of 27.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 145% over the past three years.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improved over the past weekAfter last week's 19% share price gain to ৳68.20, the stock trades at a trailing P/E ratio of 22.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 93% over the past three years.Reported Earnings • Jul 04Third quarter 2021 earnings released: EPS ৳0.95 (vs ৳0.61 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ৳2.44b (up 68% from 3Q 2020). Net income: ৳222.3m (up 55% from 3Q 2020). Profit margin: 9.1% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳51.80, the stock is trading at a trailing P/E ratio of 19x, up from the previous P/E ratio of 16.1x. This compares to an average P/E of 21x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders over the past three years are 20%.Reported Earnings • Feb 02Second quarter 2021 earnings released: EPS ৳1.21 (vs ৳0.97 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: ৳2.39b (up 56% from 2Q 2020). Net income: ৳282.9m (up 25% from 2Q 2020). Profit margin: 12% (down from 15% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 1% per year.Is New 90 Day High Low • Dec 28New 90-day high: ৳57.30The company is up 3.0% from its price of ৳55.50 on 29 September 2020. The Bangladeshi market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.Reported Earnings • Nov 22First quarter 2021 earnings released: EPS ৳0.82The company reported a mediocre first quarter result with weaker earnings and profit margins, although revenues were improved. First quarter 2021 results: Revenue: ৳2.93b (up 32% from 1Q 2020). Net income: ৳191.1m (down 30% from 1Q 2020). Profit margin: 6.5% (down from 12% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year.Is New 90 Day High Low • Nov 11New 90-day low: ৳43.50The company is down 3.0% from its price of ৳45.00 on 13 August 2020. The Bangladeshi market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.お知らせ • Nov 10Orion Pharma Limited, Annual General Meeting, Dec 23, 2020Orion Pharma Limited, Annual General Meeting, Dec 23, 2020, at 16:00 Bangladesh Standard Time. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Orion Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DSE:ORIONPHARM - アナリストの将来予測と過去の財務データ ( )BDT Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20263,011-595401822N/A12/31/20252,369-438118717N/A9/30/20253,230-540784822N/A6/30/20254,082-4153371,104N/A3/31/20256,192-109-242,096N/A12/31/20247,383-16-1481,956N/A9/30/20248,658197-7391,110N/A6/30/202410,621318-3621,587N/A3/31/202411,496455-1,2211,615N/A12/31/202311,759480-2,3331,805N/A9/30/202313,622648-1,2102,875N/A6/30/202313,927641-1,3662,493N/A3/31/202316,793700-5561,960N/A12/31/202215,633821-682,038N/A9/30/202212,389945-8591,332N/A6/30/20229,662846-1,5051,162N/A3/31/20226,150961-3,1351,637N/A12/31/20217,451938-1,6562,483N/A9/30/20219,091818-2,5692,607N/A6/30/202110,833939-1,6852,592N/A3/31/202110,193718-2743,003N/A12/31/20209,208639-1,0741,702N/A9/30/20208,3505831971,764N/A6/30/20207,6486663391,882N/A3/31/20207,210823-1,297414N/A12/31/20196,988901N/A1,011N/A9/30/20197,352928N/A1,295N/A6/30/20198,705882N/A1,449N/A3/31/20199,485859N/A1,861N/A12/31/201810,802798N/A2,236N/A9/30/201811,145772N/A2,215N/A6/30/201810,423802N/A2,194N/A3/31/201810,327734N/A2,258N/A12/31/201710,085705N/A2,622N/A9/30/20179,773779N/A2,531N/A6/30/20179,534794N/A2,251N/A3/31/20179,6851,044N/A2,199N/A12/31/20169,569988N/A2,245N/A9/30/20169,722985N/A2,653N/A6/30/20169,867882N/A2,593N/A9/30/201510,417778N/A2,558N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ORIONPHARMの予測収益成長が 貯蓄率 ( 4.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ORIONPHARMの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ORIONPHARMの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ORIONPHARMの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ORIONPHARMの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ORIONPHARMの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/25 17:35終値2026/07/23 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Orion Pharma Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Farzana Khan was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 24Orion Pharma Limited to Report Q3, 2026 Results on Apr 29, 2026Orion Pharma Limited announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 25Orion Pharma Limited to Report Q2, 2026 Results on Jan 29, 2026Orion Pharma Limited announced that they will report Q2, 2026 results on Jan 29, 2026
お知らせ • Nov 12Orion Pharma Limited, Annual General Meeting, Dec 23, 2025Orion Pharma Limited, Annual General Meeting, Dec 23, 2025, at 16:00 Central Asia Standard Time. Location: hybrid platform at orion house, 153-154, tejgaon i/a, dhaka-1208, dhaka Bangladesh
お知らせ • Nov 11Orion Pharma Limited to Report Q1, 2026 Results on Nov 15, 2025Orion Pharma Limited announced that they will report Q1, 2026 results on Nov 15, 2025
お知らせ • Nov 04Orion Pharma Limited to Report Fiscal Year 2025 Results on Nov 11, 2025Orion Pharma Limited announced that they will report fiscal year 2025 results on Nov 11, 2025
お知らせ • Apr 23Orion Pharma Limited to Report Q3, 2025 Results on Apr 29, 2025Orion Pharma Limited announced that they will report Q3, 2025 results on Apr 29, 2025
お知らせ • Jan 26Orion Pharma Limited to Report Q2, 2025 Results on Jan 29, 2025Orion Pharma Limited announced that they will report Q2, 2025 results on Jan 29, 2025
Declared Dividend • Nov 16Dividend of ৳1.00 announcedDividend of ৳1.00 is the same as last year. Ex-date: 5th December 2024 Payment date: 26th January 2025 Dividend yield will be 2.3%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (51% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 86 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 43% to shift the payout ratio to a potentially unsustainable range, which is more than the 12% EPS decline seen over the last 5 years.
お知らせ • Nov 14Orion Pharma Limited, Annual General Meeting, Dec 26, 2024Orion Pharma Limited, Annual General Meeting, Dec 26, 2024, at 15:30 Central Asia Standard Time.
お知らせ • Nov 08Orion Pharma Limited to Report Fiscal Year 2024 Results on Nov 13, 2024Orion Pharma Limited announced that they will report fiscal year 2024 results on Nov 13, 2024
New Risk • Nov 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.2% operating cash flow to total debt). Earnings have declined by 6.1% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (৳9.73b market cap, or US$81.3m).
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ৳37.80, the stock trades at a trailing P/E ratio of 19.4x. Average trailing P/E is 18x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 57% over the past three years.
Valuation Update With 7 Day Price Move • Oct 02Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ৳34.10, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 68% over the past three years.
New Risk • Aug 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ৳11.8b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.2% operating cash flow to total debt). Earnings have declined by 6.1% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (৳11.8b market cap, or US$98.7m).
Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳0.42 (vs ৳0.53 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.42 (down from ৳0.53 in 3Q 2023). Revenue: ৳2.04b (down 11% from 3Q 2023). Net income: ৳99.2m (down 20% from 3Q 2023). Profit margin: 4.9% (down from 5.4% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
お知らせ • Apr 26Orion Pharma Limited to Report Q3, 2024 Results on Apr 29, 2024Orion Pharma Limited announced that they will report Q3, 2024 results on Apr 29, 2024
New Risk • Dec 19New major risk - Revenue and earnings growthEarnings have declined by 1.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (13% operating cash flow to total debt). Debt is not well covered by operating cash flow (13% operating cash flow to total debt). Earnings have declined by 1.8% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (4.8% net profit margin). Profit margins are more than 30% lower than last year (4.8% net profit margin).
Upcoming Dividend • Nov 27Upcoming dividend of ৳1.00 per share at 1.3% yieldEligible shareholders must have bought the stock before 04 December 2023. Payment date: 25 January 2024. Payout ratio is a comfortable 33% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).
お知らせ • Nov 14Orion Pharma Limited, Annual General Meeting, Dec 26, 2023Orion Pharma Limited, Annual General Meeting, Dec 26, 2023, at 15:00 Bangladesh Standard Time.
お知らせ • Nov 13Orion Pharma Limited to Report Q1, 2024 Results on Nov 14, 2023Orion Pharma Limited announced that they will report Q1, 2024 results on Nov 14, 2023
お知らせ • Nov 07Orion Pharma Limited to Report Fiscal Year 2023 Results on Nov 12, 2023Orion Pharma Limited announced that they will report fiscal year 2023 results on Nov 12, 2023
Reported Earnings • May 06Third quarter 2023 earnings released: EPS: ৳0.53 (vs ৳1.05 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.53 (down from ৳1.05 in 3Q 2022). Revenue: ৳2.30b (up 102% from 3Q 2022). Net income: ৳123.9m (down 50% from 3Q 2022). Profit margin: 5.4% (down from 22% in 3Q 2022). The decrease in margin was driven by higher expenses.
Reported Earnings • Feb 14Second quarter 2023 earnings released: EPS: ৳1.19 (vs ৳1.72 in 2Q 2022)Second quarter 2023 results: EPS: ৳1.19 (down from ৳1.72 in 2Q 2022). Revenue: ৳4.00b (up 430% from 2Q 2022). Net income: ৳278.4m (down 31% from 2Q 2022). Profit margin: 7.0% (down from 53% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Nov 28Upcoming dividend of ৳1.00 per shareEligible shareholders must have bought the stock before 05 December 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).
Valuation Update With 7 Day Price Move • Nov 20Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ৳85.00, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 196% over the past three years.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director A. N. M. Kashem was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Nov 15Orion Pharma Limited Recommends Cash Dividend for the Year Ended June 30, 2022Orion Pharma Limited Board of Directors has recommended 10% cash dividend for the year ended June 30, 2022.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ৳113, the stock trades at a trailing P/E ratio of 27.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 340% over the past three years.
Valuation Update With 7 Day Price Move • Sep 22Investor sentiment improved over the past weekAfter last week's 29% share price gain to ৳150, the stock trades at a trailing P/E ratio of 36.4x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 432% over the past three years.
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to ৳126, the stock trades at a trailing P/E ratio of 30.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 349% over the past three years.
Valuation Update With 7 Day Price Move • Aug 24Investor sentiment improved over the past weekAfter last week's 15% share price gain to ৳103, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 244% over the past three years.
Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳92.10, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 21x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 197% over the past three years.
Reported Earnings • Apr 30Third quarter 2022 earnings released: EPS: ৳1.05 (vs ৳0.95 in 3Q 2021)Third quarter 2022 results: EPS: ৳1.05 (up from ৳0.95 in 3Q 2021). Revenue: ৳1.14b (down 53% from 3Q 2021). Net income: ৳245.5m (up 10% from 3Q 2021). Profit margin: 22% (up from 9.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director A. N. M. Kashem was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 01Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳1.72 (up from ৳1.21 in 2Q 2021). Revenue: ৳754.3m (down 69% from 2Q 2021). Net income: ৳402.3m (up 42% from 2Q 2021). Profit margin: 53% (up from 12% in 2Q 2021). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 42% per year, which means it is well ahead of earnings.
Upcoming Dividend • Nov 23Upcoming dividend of ৳1.20 per shareEligible shareholders must have bought the stock before 30 November 2021. Payment date: 18 January 2022. Trailing yield: 1.2%. Lower than top quartile of Bangladeshi dividend payers (2.9%). Lower than average of industry peers (1.7%).
Valuation Update With 7 Day Price Move • Oct 11Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳112, the stock trades at a trailing P/E ratio of 36.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 231% over the past three years.
Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improved over the past weekAfter last week's 24% share price gain to ৳84.40, the stock trades at a trailing P/E ratio of 27.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 145% over the past three years.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improved over the past weekAfter last week's 19% share price gain to ৳68.20, the stock trades at a trailing P/E ratio of 22.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 93% over the past three years.
Reported Earnings • Jul 04Third quarter 2021 earnings released: EPS ৳0.95 (vs ৳0.61 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ৳2.44b (up 68% from 3Q 2020). Net income: ৳222.3m (up 55% from 3Q 2020). Profit margin: 9.1% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳51.80, the stock is trading at a trailing P/E ratio of 19x, up from the previous P/E ratio of 16.1x. This compares to an average P/E of 21x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders over the past three years are 20%.
Reported Earnings • Feb 02Second quarter 2021 earnings released: EPS ৳1.21 (vs ৳0.97 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: ৳2.39b (up 56% from 2Q 2020). Net income: ৳282.9m (up 25% from 2Q 2020). Profit margin: 12% (down from 15% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 1% per year.
Is New 90 Day High Low • Dec 28New 90-day high: ৳57.30The company is up 3.0% from its price of ৳55.50 on 29 September 2020. The Bangladeshi market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
Reported Earnings • Nov 22First quarter 2021 earnings released: EPS ৳0.82The company reported a mediocre first quarter result with weaker earnings and profit margins, although revenues were improved. First quarter 2021 results: Revenue: ৳2.93b (up 32% from 1Q 2020). Net income: ৳191.1m (down 30% from 1Q 2020). Profit margin: 6.5% (down from 12% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year.
Is New 90 Day High Low • Nov 11New 90-day low: ৳43.50The company is down 3.0% from its price of ৳45.00 on 13 August 2020. The Bangladeshi market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
お知らせ • Nov 10Orion Pharma Limited, Annual General Meeting, Dec 23, 2020Orion Pharma Limited, Annual General Meeting, Dec 23, 2020, at 16:00 Bangladesh Standard Time.